vector and co-transfected these reporters with miR-150-3p mimics in NSCLC cells. We tested the expression levels of SRCIN1 and miR-150-3p in 163 NSCLC tumor tissues and the results demonstrated that the negative correlation between miR-150-3p and SRCIN1 expression levels. NSCLC cells were transfected with miR-150-3p mimics or miR-150-3p inhibitor.To verify the biological significance of LincRNA00494 on tumor growth, xenograft was carried out via subcutaneous injection with NSCLC cells. Results: LincRNA00494 was down-regulated in tumor tissues compared with adjacent nontumor tissues. The expression of Linc00494 was positively correlated with SRCIN1. Silencing LincRNA00494 in H358 and H1299 cells substantially decreased SRCIN1 expression at mRNA and protein levels, whereas LincRNA00494 overexpression improved SRCIN1 levels. MiR-150-3p significantly decreased the luciferase signals of both LINCRNA00494 and SRCIN1 reporters. And there is negative correlation between miR-150-3p and SRCIN1 expression levels. MiR-150-3p could target LincRNA00494 and SRCIN1, in addition, LincRNA00494 modulated the expression of SRCIN1 as a molecular decoy for miR-150-3p. Physiological overexpression of LincRNA00494 decreased cell proliferation of the H358 and H1299 cell lines compared with control by CCK-8 assay. In xenograft, tumor growth from overexpressed LincRNA00494 xenograft was significantly decreased. Conclusion: LincRNA00494 might improve SRCIN1 expression by competing for miR-150-3p, subsequently mediating cell proliferation in NSCLC. Keywords: LincRNA00494, ceRNA, nsclc Background: Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that is clinically effective as a first-line and second-line therapy in patients with EGFRmutated non-small-cell lung cancer (NSCLC). Use of this treatment is limited by high costs. Here, we conducted a cost-effectiveness analysis of different sequences of osimertinib administration in China and the United States. Method: We established Markov models based on data from the FLAURA and AURA3 trials, which included patients with EGFR mutation-positive advanced NSCLC. The cost-effectiveness analysis compared first-line osimertinib to first-generation EGFR-TKIs or second-line osimertinib after the failure of first-generation EGFR-TKIs. The analysis also considered different payment modalities available in China. Additionally, we performed 1-way sensitivity and probability sensitivity analyses with a willingness-to-pay threshold (WTP) of 3Â the per capita gross domestic product ($27783/quality-adjusted life year [QALY] for China and $100000/QALY for the United States). Results: In the base case analysis, second-line osimertinib was associated with higher cumulative QALYs, lower costs, and negative incremental cost-effectiveness ratios (ICERs) compared to first-line osimertinib in China and the United States. In contrast, QALYs and costs were higher in the first-line osimertinib group than in the first-line first-generation EGFR-TKI group, with an ICER of $212252/QALY in China and $151922/QALY in the United States. In the subgroup analysis, osimertinib company donation was the most economic and beneficial option in China. One-way sensitivity analyses highlighted the influence of utilities in different states. Cost-effective acceptability curves indicated that a higher WTP threshold was necessary for first-line osimertinib to be cost-effective. Conclusion: First-line osimertinib therapy was not more cost-effective than second-line osimertinib therapy after the failure of first-generation EGFR-TKIs or first-line first-generation EGFR-TKIs. Keywords: cost-effectiveness, EGFR tyrosine kinase inhibitor, lung cancer, osimertinib Background: Non-small-cell lung cancer (NSCLC) patients with brain metastases had a poor prognosis and quality of life. Despite the traditional methods including radiotherapy and chemotherapy, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFRTKIs) might benefit patients on survival and quality of life. We investigated the cost-effectiveness of icotinib compared with WBI with or without chemotherapy for NSCLC patients with brain metastases. Method: A markov model was conducted based on the data of BRAIN trial. We compared the economic benefit among icotinib, whole-brain irradiation (WBI) alone group, WBI plus chemotherapy group, and the combination of WBI and WBI plus chemotherapy group. We considered disease progression as intracranial progression and overall progression separately. Sensitivity analyses were performed to observe the stability of the model. The willingness-topay (WTP) was set as 3Â per capita gross domestic product ($25929/quality-adjusted life year [QALY]). Results: When considering progression as intracranial progression and overall progression respectively, the incremental cost-effectiveness ratio (ICER) was $822.57/QALY and $763.03/QALY between icotinib and WBI; $908.14/QALY and $837.65/QALY between icotinib with WBIchemotherapy; $881.55 /QALY and $814.5/ QALY between icotinib and WBI/WBI-chemotherapy. Besides, both of the average costeffective ratio (average CE) and net benefit showed advantage of icotinib (average CE: $2193.43/QALY for intracranial progression, $2338.10/QALY for overall progression; net benefit: $395728.16 for intracranial progression, $368976.82 for overall progression). Oneway sensitivity analyses demonstrated the importance of the utilities of icotinib group. The probabilistic sensitivity analyses showed even at a WTP under $6000/QALY, icotinib could be cost-effective comparing with WBI. Conclusion: Icotinib was cost-effective compared with WBI with or without chemotherapy.
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